447 Evaluation of efficacy and toxicity of human CD40 agonistic antibodies in C57BL/6-hCD40/hFcγRIIB HuGEMMTM

• Lei Zheng,
• Rong Wang,
• Jie Lin,
• Xuefei Yan,
• Xiaoxi Xu,
• Xinhe Feng,
• Annie An,
• Jessie Wang,
• Kaixia Lian,
• Ludovic Bourre,
• Xiaolong Tu,
• Demi X Liu,
• Chengcheng Wang

Affiliations

Lei Zheng

The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA

Rong Wang

Department of Adult Cardiovascular Surgery, Sixth Medical Center of PLA General Hospital, Beijing, China

Jie Lin

Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Youjiang Medical University for Nationalities, Baise, Guangxi, China

Xuefei Yan

Crown Bioscience, San Diego, CA, USA

Xiaoxi Xu

2Crown Bioscience Inc., San Diego, CA, USA

Xinhe Feng

1Crown Bioscience Inc., San Diego, CA, USA

Annie An

1Crown Bioscience Inc., San Diego, CA, USA

Jessie Wang

2Crown Bioscience Inc., San Diego, CA, USA

Kaixia Lian

Crown Bioscience Inc., Taicang, Suzhou, China

Ludovic Bourre

4Crown Bioscience, Paris, France

Xiaolong Tu

1Crown Bioscience Inc, San Diego, CA, United States

Demi X Liu

1Crown Bioscience, Beijing, China

Chengcheng Wang

2Crown Bioscience Inc., San Diego, CA, USA